当前位置: 首页 » 论文全文
←返回首页
期刊信息:
《药学服务与研究》2019年, 第19卷, 第1期, 第1-4页
标题:
GLP-1受体激动剂与SGLT-2抑制剂在2型糖尿病中安全性的研究进展
DOI:
10.5428/pcar20190101
作者:
1. 李文文(海军军医大学长海医院内分泌科 上海 200433 liwenwen19960130@126.com)
2. 王奇金(海军军医大学长海医院内分泌科 上海 200433 wangqi jin8668601@163.com)
摘要:
摘要  胰高糖素样肽-1(glucagon-like peptide-1,GLP-1)受体激动剂、钠-葡萄糖共转运蛋白2(sodium glucose cotransporter 2,SGLT2)抑制剂作为2型糖尿病降糖治疗的新药,目前已广泛用于临床。本文总结了这两类药物的安全性,即对低血糖与糖尿病酮症酸中毒的影响,以及对各个系统,即心血管系统、消化系统、泌尿生殖系统、骨骼系统及甲状腺等可能产生的影响,可在临床中指导安全用药,最大限度地发挥这两类药物在2型糖尿病治疗中的优势。
欢迎阅读《药学服务与研究》!您是该文第 255 位读者!
若需在您的论文中引用此文,请按以下格式著录参考文献:
中文著录格式 李文文,王奇金. GLP-1受体激动剂与SGLT-2抑制剂在2型糖尿病中安全性的研究进展[J]. 药学服务与研究. 2019; 19(1): 1-4.
英文著录格式 LI Wenwen,WANG Qijin. Safety of GLP-1 receptor agonists and SGLT-2 inhibitors in type 2 diabetes mellitus[J]. Pharmaceutical Care and Research / yao xue fu wu yu yan jiu. 2019; 19(1): 1-4.
参考文献:
1. 中华医学会糖尿病学分会.中国2型糖尿病防治指南(2017年版)[J].中华糖尿病杂志,2018,10(1):4-67.
2. Levin P A.Practical combination therapy based on pathophysiology of type 2 diabetes[J].Diabetes Metab Syndr Obes Targets Ther,2016,9:355-369.
3. Wilding J P H,Rajeev S P,DeFronzo R A.Positioning SGLT2 inhibitors/incretin-based therapies in the treatment algorithm[J].Diabetes Care,2016,39(2):S154-S164.
4. Miller M E,Williamson J D,Gerstein H C,et al.Effects of randomization to intensive glucose control on adverse events,cardiovascular disease,and mortality in older versus younger adults in the ACCORD Trial[J].Diabetes Care,2014,37(3): 634-643.
5. Seaquist E R,Miller M E,Bonds D E,et al.The impact of frequent and unrecognized hypoglycemia on mortality in the ACCORD study[J].Diabetes Care,2012,35(2):409-414.
6. Consoli A,Formoso G,Baldassarre M P A,et al.A comparative safety review between GLP-1 receptor agonists and SGLT2 inhibitors for diabetes treatment[J].Expert Opin Drug Saf,2018,DOI:10.1080/14740338.2018.1428305.
7. Ogawa W,Sakaguchi K.Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors:possible mechanism and contributing factors[J].J Diabetes Investig,2016,7(2):135-138.
8. Yokono M,Takasu T,Hayashizaki Y,et al.SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats[J].Eur J Pharmacol,2014,727(1):66-74.
9. Goldenberg R M,Berard L D,Cheng A Y Y,et al.SGLT2 inhibitor associated diabetic ketoacidosis: clinical review and recommendations for prevention and diagnosis[J].Clin Ther,2016,38(12):2654-2664.
10. Marso S P,Bain S C,Consoli A,et al.Semaglutide and cardiovascular outcomes in paitients with type 2 diabetes[J].N Engl J Med,2016,375(19):1834-1844.
11. Lovshin J A.Glucagon-like peptide receptor agonists: a class update for treating type 2 diabetes[J].Can J Diabetes,2017,41(5):524-535.
12. Goud A,Zhong Jixin,Peters M,et al.GLP-1 agonists and blood pressure: a review of the evidence[J].Curr Hypertens Rep,2016,18(2):16.
13. Neal B,Perkovic V,Mahaffey K W,et al.Canagliflozin and cardiovascular and renal events in type 2 diabetes[J].N Engl J Med,2017,377(7):644-657.
14. Scheen A J.GLP-1 receptor agonists and heart failure in diabetes[J].Diabetes Metab,2017,43:2S13-2S19.
15. Wanner C,Inzucchi S E,Lachin J M,et al.Empagliflozin and progression of kidney disease in type 2 diabetes[J].N Engl J Med,2016,375(4):323-334.
16. Marso S P,Daniels G H,Brown-Frandsen K,et al.Liraglutide and cardiovascular outcomes in type 2 diabetes[J].N Engl J Med,2016,375(4):311-322.
17. Sikirica M V,Martin A A,Wood R,et al.Reasons for discontinuation of GLP-1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes[J].Diabetes Metab Syndr Obes,2017,10:403-412.
18. YANG Lin,HE Zhiyu,TANG Xulei,et al.Type 2 diabetes mellitus and the risk of acute pancreatitis: a meta-analysis[J].Eur J Gastroenterol Hepatol,2013,25:225-231.
19. Elashoff M,Matveyenko A V,Gier B,et al.Pancreatitis,pancreatic,and thyroid cancer with glucagon-like peptide-1-based therapies[J].Gastroenterology,2011,141:150-156.
20. Neumiller J J,Alicic R Z,Tuttle K R.Therapeutic considerations for antihyperglycemic agents in diabetic kidney disease[J].J Am Soc Nephrol,2017,28(8):2263-2274.
21. ZOU Honghong,ZHOU Baoqin,XU Gaosi.SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease[J].Cardiovasc Diabetol,2017,16:65.
22. McHugh K R,DeVore A D,Mentz R J,et al.The emerging role of novel antihyperglycemic agents in the treatment of heart failure and diabetes: a focus on cardiorenal outcomes[J].Clin Cardiol,2018,41:1259-1267.
23. Nauck M A.Update on developments with SGLT2 inhibitors in the management of type 2 diabetes[J].Drug Des Devel Ther,2014,8:1335-1380.
24. LIU Jiali,LI Ling,LI Sheyu,et al.Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis[J].Sci Rep,2017,7:1-11.
25. Wilding J P,Woo V,Soler N G,et al.Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin[J].Dtsch Med W ochenschr,2013,138(Suppl 1):S27-S38.
26. LUO Guojing,LIU Hong,LU Hongyun.Glucagon-like peptide-1(GLP-1) receptor agonists: potential to reduce fracture risk in diabetic patients?[J].Br J Clin Pharmacol,2016,81(1):78-88.
27. Kohler S,Salsali A,Hantel S,et al.Safety and tolerability of empagliflozin in patients with type 2 diabetes[J].Clin Ther,2016,38:1299-1313.
28. Ljunggren ,Bolinder J,Johansson L,et al.Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin[J].Diabetes Obes Metab,2012,14:990-999.
29. Bjerre Knudsen L,Madsen L W,Andersen S,et al.Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation[J].Endocrinology,2010,151:1473-1486.
30. Hegedüs L,Moses A C,Zdravkovic M,et al.GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog,liraglutide[J].J Clin Endocrinol Metab,2011,96(3):853-860.
31. Mathieu P,Boulanger M C,Despres J P.Ectopic visceral fat: a clinical and molecular perspective on the cardiometabolic risk[J].Rev Endocr Metab Disord,2014,15(4):289-298.